The 2026 Annual Meeting of the China Entrepreneurs Forum was held from March 17 to 19 in Yabuli, Heilongjiang Province. Xie Chengrun, CEO of Sino Biopharmaceutical Limited and Chairman of Zhengda Tianqing and Beijing Tide Pharmaceutical, stated that data shows a significant increase in the number of new molecular entities launched in China compared to 48 in 2024, setting a new record. China has become the world's second-largest country for new molecular entity launches, reflecting widespread global recognition of the value of domestically developed innovative drugs.

He pointed out that China is currently experiencing a boom in innovation-driven pharmaceutical engineering talent, with scientific research, development, clinical infrastructure, and research capabilities entering a period of rapid growth. Leveraging a complete R&D system and efficient implementation capabilities, domestic companies can quickly follow up on cutting-edge discoveries, take the lead in advancing Phase I and II clinical trials for novel molecules, and complete proof-of-concept validation, significantly enhancing industrial innovation efficiency and competitiveness.

Currently, global pharmaceutical companies are paying close attention to China's innovative drug assets. U.S. multinational corporations are actively coming to China to acquire promising candidates, seeking new drug targets, and engaging in early-stage AI-driven R&D collaborations.